SERA PROGNOSTICS, INC.
Close on Oct 19, 2026
- Market cap
- $102.47M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $30.00K | $-0.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | After market close | $14.00K | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | After market close | $10.00K | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $17.00K | $-0.16 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $38.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | After market close | $24.00K | $-0.25 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 20, 2024 | After market close | – | – | – |
Press releases
Announcements Sera Prognostics filed with the SEC
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
JANUARY 2026 We are redefining pregnancy care to reduce the burden of preterm birth
Regulation FD disclosure · EX-99.1 to Form 8-K
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Regulation FD disclosure · EX-99.1 to Form 8-K
Sera Announces Publication Acceptance for PRIME Study
Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
September 2025 We are redefining pregnancy care to reduce the burden of preterm birth Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER
Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Sera Prognostics Announces Proposed Public Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sera Prognostics Announces Pricing of $50 Million Public Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
transform the experience into one with fewer uncertainties ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States.
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Next Milestones Publications Commercialization: Driving Next Inflection Point Reimbursement Guidelines Regulatory Additional Evidence ©2025 Sera Prognostics, Inc. All rights reserved. PreTRM, Sera Prognostics and their logos are trademarks or registered trademarks of Sera Prognostics, Inc. in the…
Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
WE AIM to change pregnancy care, to transform the experience into one with fewer uncertainties.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET
Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
SERA PROGNOSTICS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K